Allergy and Immunology Vol. II

Food & Drug Allergy

Peanut and multi-food oral immunotherapy, early peanut introduction and the NIAID addendum, sustained-unresponsiveness testing, cross-reactive pollen-food syndrome, alpha-gal syndrome and cetuximab cross-reactivity, FPIES resolution testing, penicillin allergy delabeling, unverified perioperative drug-allergy labels, severe cutaneous drug reactions, radiocontrast premedication versus agent switching, aspirin/NSAID desensitization after PCI, epinephrine route selection, and biphasic-reaction prevention

Eosinophilic/GI Disorders

Eosinophilic esophagitis first-line therapy selection, allergy-testing-directed versus empiric elimination diets, maintenance de-escalation after remission, hypereosinophilic syndrome therapy selection, eosinophilic gastroenteritis, EoE with comorbid celiac disease or Crohn's disease, food protein-induced allergic proctocolitis, FDA-approved versus compounded topical steroid formulations, the retired PPI-trial requirement, and elemental formula versus elimination diet in pediatric failure to thrive

Mast Cell, Anaphylaxis and Other Hypersensitivity

Idiopathic anaphylaxis prophylaxis, systemic mastocytosis and cytoreductive therapy, mast cell activation syndrome, hereditary alpha-tryptasemia and venom immunotherapy duration, food- and non-food-dependent exercise-induced anaphylaxis, latex-fruit cross-reactivity, biologic-induced anaphylaxis and rechallenge decisions, beta-blocker-refractory anaphylaxis management, Kounis syndrome, REMA-guided bone marrow biopsy thresholds, epinephrine autoinjector needle-length adequacy, omalizumab as steroid-sparing therapy, and monoclonal mast cell activation syndrome